DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema
Recruiting
Phase 4
Interventional Study
Atopic Dermatitis
Atopic Dermatitis Eczema
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 216 (estimated)
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this randomized controlled trial is to study the (cost)effectiveness of extending the intervals between dupilumab doses in patients with well-controlled atopic eczema, while considering physician- and patient-reported disease severity, quality of life, and dupilumab serum trough levels. Patients will be divided randomly into three groups, receiving dupilumab 300 mg every 2 weeks, every…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* The subject is an adult,
* Has a diagnosis of AE,
* Receives dupilumab 300 mg q2w for the treatment of AE,
* Has controlled disease according to the Treat-to-Target criteria,
* Agrees to the possibility that the dosage of dupilumab will be lowered,
* Has voluntarily signed and…
Contacts